Development of target-based antineoplastic agents

Investigational New Drugs

Volumn 18, Issue 1, 2000, Pages 7-16

  Stadler, Walter M ^a,b   Ratain, Mark J ^b  

^a SECTION OF HEMATOLOGY ONCOLOGY   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Clinical trial design; Cytostatic drugs

Indexed keywords

5 AMINO 1 [3,5 DICHLORO 4 (4 CHLOROBENZOYL)BENZYL] 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; 6 O BENZYLGUANINE; ANTINEOPLASTIC AGENT; CYTOSTATIC AGENT; CYTOTOXIC AGENT; IND 38583; KETOCONAZOLE; RITONAVIR; UNCLASSIFIED DRUG;

CANCER CELL; CLINICAL TRIAL; DRUG CYTOTOXICITY; DRUG DEVELOPMENT; DRUG TARGETING; HUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; TUMOR BIOPSY;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DRUG DESIGN; HUMANS; NEOPLASMS; RESEARCH DESIGN;

EID: 0034111270     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006371512390     Document Type: Review

References (29)

1. Yang W, Del-Villar K, Urano J, et al.: Advances in the development of farnesyltransferase inhibitors: substrate recognition by protein famesyltransferase. J Cell Biochem Suppl 27: 12-19, 1997
2. Denis LJ, Verweij J: Matrix metalloproteinase inhibitors: present achievements and future prospects. Invest New Drugs 15: 175-185, 1997
3. Harris AL: Antiangiogenesis for cancer therapy. Lancet 349 (Suppl 2): SII13-5, 1997
4. Biggs JR, Kraff AS: Inhibitors of cyclin-dependent kinase and cancer. J Mol Med 73: 509-514, 1995
5. Ingber D, Fujita T, Kishimoto S, et al.: Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature 348: 55-57, 1990
6. Sledge GW Jr, Qulali M, Goulet R, et al.: Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. J Natl Cancer Inst 87: 1546-1550, 1995
7. Kohn EC, Reed E, Sarosy G, et al.: Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers. Cancer Res 56: 569-573, 1996
8. Davis KL, Thai LJ, Gamzu ER, et al.: A double blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. N Engl J Med 327: 1306-1308, 1992
9. Holford NH, Peace KE: Results and validation of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. Proc Natl Acad Sci USA 89: 11471-11475, 1992
10. Bensimon G, Lacomblez L, Meininger V: A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 330: 585-591, 1994
11. Paulus HE, Egger MJ, Ward JR, et al.: Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. Arthritis Rheum 33: 477-484, 1990
12. Porter DR, Capell HA: The 'natural' history of active rheumatoid arthritis over 36 months - an analysis of patients enrolled into trials of potential disease-modifying anti-rheumatic drugs, and treated with placebo. Br J Rheumatol 32: 463-466, 1993
13. Kirwan JR: The effect of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med 333: 142-146, 1995
14. Ferraccioli GF, Della-Casa-Alberighi O, Marubini E, et al.: Is the control of disease progression within our grasp? Review of the GRISAR study. (Gruppo Reumatologi Italiani Studio Artrite Reumatoide). Br J Rheumatol 35 Suppl 2: 8-13, 1996
15. Ratain MJ, Mick R, Schilsky RL, et al.: Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. J Natl Cancer Inst. 85: 1637-1643, 1993
16. Millar AW, Brown PD, Moore J, et al.: Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers. Br J Clin Pharmacol 45: 21-26, 1998
17. Mani S, Ratain MJ: New phase I trial methodology. Semin Oncol 24: 253-261, 1997
18. Paxton JW, Kim SN, Whitfield LR: Pharmacokinetic and toxicity scaling of the antitumor agents amsacrine and CI-921, a new analogue, in mice, rats, rabbits, dogs, and humans. Cancer Res 50: 2692-2697, 1990
19. DeMario MD, Ratain MJ: Oral chemotherapy: rationale and future directions. J Clin Oncol 16: 2557-2567, 1998
20. Merry C, Barry MG, Mulcahy F, et al.: Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 11: F29-33, 1997
21. Keogh A, Spratt P, McCosker C, et al.: Ketoconazole to reduce the need for cyclosporine after cardiac transplantation. N Engl J Med 333: 628-633, 1995
22. Floren LC, Bekersky I, Benet LZ, et al.: Tacrolimus oral bioavailability doubles with coadminstration of ketoconazole. Clin Pharmacol Ther 62: 41-49, 1997
23. Spiro TP, Gerson SL, Hoppel CL, et al.: O6-Benzylguanine totally depletes alkylguanine DNA alkyltransferase in tumor tissue: A phase I phannacokinetic/pharmacodynamic study. Proc Amer Soc Clin Oncol 17: 212a, 1998
24. Eisenhauer EA: Phase I and II trials of novel anti-cancer agents: endpoints, efficacy and existentialism. Am Oncol 9: 1047-1052, 1998
25. Von Hoff DD: There are no bad anticancer agents, only bad clinical trial designs - twenty-first Richard and Hinda Rosenthal Foundation Award Lecture. Clin Cancer Res 4: 1079-1086, 1998
26. Nemunaitis J, Poole C, Primrose J, et al.: Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. Clin Cancer Res 4: 1101-1109, 1998
27. Lippman SM, Hong WK, Benner SE. The chemoprevention of cancer, in Greenwals P, Kramer BS, Weed DL (eds). Cancer Prevention and Control. New York, NY: Marcel Dekker, Inc, 1995, pp 329-352
28. Kopec JA, Abrahamowicz M, Esdaile JM: Randomized discontinuation trials: Utility and efficiency. J Clin Epidemiol 46: 959-971, 1993
29. Tannock IF, Osoba D, Stockier MR, Ernst DS, Neville AJ, Moore MJ, Annitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 6: 1756-1764, 1996